Skip to main content
SpringerLink
Log in

Afatinib/osimertinib

Acquired drug resistance and rebound of brain metastases: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Blaquier JB, et al. Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S. Journal of Chemotherapy 35: 168-172, No. 2, 25 Apr 2022. Available from: URL: https://www.tandfonline.com/toc/yjoc20/35/2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/osimertinib. Reactions Weekly 1983, 21 (2023). https://doi.org/10.1007/s40278-023-49370-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-49370-8

Search

Navigation